by
Fri, Apr 20 2012 13:53:29

AACR 2012: ABT-199 shows promise in CLL

At the 2012 annual meeting of the American Association for Cancer Research (AACR), Steven W. Elmore from Abbott Laboratories presented impressive initial data on ABT-199, a potent and selective inhibitor of Bcl-2, currently in a phase I clinical trial for Chronic Lymphocytic Leukemia (CLL).

  1. New drugs on the horizon being discussed at #aacr include AZD3514 SAR299155 ABT-199 http://pic.twitter.com/atcEafd6
    Pieter Droppert@3NT
    ·
    Sun, Apr 01 2012 13:09:49
  2. 3NT
    Pieter Droppert@3NT
    Steven Elmore from Abbott to discuss ABT-199 at #aacr
    Sun, Apr 01 2012 13:18:31
  3. 3NT
    Pieter Droppert@3NT
    Elmore: ABT-199 has high affinity for Bcl-2, lower affinity for Bcl- xl #aacr
    Sun, Apr 01 2012 13:29:21
  4. teamoncology
    Naoto T. Ueno 上野直人@teamoncology
    RT @3NT: Elmore: ABT-199 has high affinity for Bcl-2, lower affinity for Bcl- xl #aacr
    Sun, Apr 01 2012 13:30:06
  5. 3NT
    Pieter Droppert@3NT
    Elmore: showing animal data that ABT-199 is platelet sparing #aacr
    Sun, Apr 01 2012 13:32:04
  6. 3NT
    Pieter Droppert@3NT
    Elmore: ALL cell lines are 'primed for death' - ABT-199 induces tumor regression #aacr
    Sun, Apr 01 2012 13:34:42
  7. teamoncology
    Naoto T. Ueno 上野直人@teamoncology
    RT @3NT: Elmore: ABT-199 triggers cytochrome-c release & induces phosphatidyl-serine externalisation #aacr
    Sun, Apr 01 2012 13:34:42
  8. OracleofPharma
    Ronak Savla@OracleofPharma
    RT @3NT: Elmore: a single-dose of ABT-199 can achieve rapid reduction of CLL burden in patients with refractory disease - data at EHA 2012 #aacr
    Sun, Apr 01 2012 13:43:37
  9. 3NT
    Pieter Droppert@3NT
    Elmore: ABT-199 potently kills a subset of NHL human tumor cell lines #aacr
    Sun, Apr 01 2012 13:35:38
  10. 3NT
    Pieter Droppert@3NT
    Elmore: markers correlate with ABT-199 sensitivity in DLBCL #aacr
    Sun, Apr 01 2012 13:36:36
  11. 3NT
    Pieter Droppert@3NT
    Elmore: ABT-199 enhances the efficacy of Rituximab in murine xenograft models of DLBCL #aacr
    Sun, Apr 01 2012 13:37:50
  12. aftimosp
    Philippe Aftimos MD@aftimosp
    Synergy of the Bcl-2 inhibitor ABT-199 with rituximab in DLBCL #AACR
    Sun, Apr 01 2012 13:38:20
  13. 3NT
    Pieter Droppert@3NT
    Elmore: ABT-199 enhances the efficacy of standard treatment regimens in murine xenograft models of NHL #aacr
    Sun, Apr 01 2012 13:39:01
  14. aftimosp
    Philippe Aftimos MD@aftimosp
    Synergy of ABT-199 also demonstrated with cobination chemotherapy #AACR
    Sun, Apr 01 2012 13:39:18
  15. aftimosp
    Philippe Aftimos MD@aftimosp
    Impressive! Activity of ABT-199 in first cohort of phase 1 trial #AACR
    Sun, Apr 01 2012 13:40:47
  16. 3NT
    Pieter Droppert@3NT
    Elmore: a single-dose of ABT-199 can achieve rapid reduction of CLL burden in patients with refractory disease - data at EHA 2012 #aacr
    Sun, Apr 01 2012 13:41:09
  17. 3NT
    Pieter Droppert@3NT
    ABT-199 phase 1 data looks promising in CLL - data to be presented at EHA in June #aacr
    Sun, Apr 01 2012 13:42:40
  18. JasonCRG
    Jason Chew@JasonCRG
    @3NT That's some pretty neat stuff. ABT-199
    Sun, Apr 01 2012 16:07:30
  19. mtmdphd
    Mike Thompson, MDPhD@mtmdphd
    RT @DrNeilLove: @Charlene19 Dr Brad Kahl: "New BCL-2 inhibitor called ABT 199. In Phase I CLL tests, looking very promising early on"
    Thu, Apr 05 2012 13:57:42
  20. Pieter Droppert writes the Biotech Strategy Blog and this Storify is part of a series of posts about the 2012 annual meeting of the American Association for Cancer Research (AACR).

Did you find this story interesting? Be the first to or comment.

Liked!

Pieter Droppert

Consultant, Blogger on Science & Medicine

14stories
10followers
2following
Total views
3,778

Sorry.

This URL is already in use. Please choose another URL.
Edit URL

Storify

@Storify

Are you sure?

Are you sure you want to delete this story?

Are you sure?

Are you sure you want to flag this story?